Actinium Pharmaceuticals Grants Inducement Equity Awards to New Employee for Motivated Growth#United_States#New_York#Prostate_Cancer#AML_Treatment#Actinium
Actinium Pharmaceuticals Grants Inducement Equity Awards to New Employee for Motivated Growth
Actinium Pharmaceuticals has announced an inducement equity award to a new non-executive employee, encouraging talent while enhancing its growth strategy in targeted radiotherapies.
third-news.com
October 30, 2026 at 9:34 PM
Actinium Pharmaceuticals Grants Inducement Equity Awards to New Employee for Motivated Growth#United_States#New_York#Prostate_Cancer#AML_Treatment#Actinium
Moleculin Biotech Moves Forward with $3.5 Million Direct Offering to Fund Innovative Cancer Therapies#United_States#Houston#Cancer_Research#Moleculin_Biotech#AML_Treatment
Moleculin Biotech Moves Forward with $3.5 Million Direct Offering to Fund Innovative Cancer Therapies
Moleculin Biotech has announced a $3.5 million direct offering and private placement to support its cancer treatment developments, including groundbreaking therapies targeting AML.
third-news.com
February 25, 2025 at 5:40 PM
Moleculin Biotech Moves Forward with $3.5 Million Direct Offering to Fund Innovative Cancer Therapies#United_States#Houston#Cancer_Research#Moleculin_Biotech#AML_Treatment
Moleculin Biotech Makes Progress with FDA on Key AML Clinical Trial Approval#USA#Houston#Moleculin_Biotech#Annamycin#AML_Treatment
Moleculin Biotech Makes Progress with FDA on Key AML Clinical Trial Approval
Moleculin Biotech receives positive FDA guidance for the MIRACLE trial, accelerating the development timeline for AML treatment. This pivotal trial aims to treat hard-to-treat tumors effectively.
third-news.com
February 13, 2025 at 3:13 PM
Moleculin Biotech Makes Progress with FDA on Key AML Clinical Trial Approval#USA#Houston#Moleculin_Biotech#Annamycin#AML_Treatment